Company intelligence / Profile preview

Lucigen

Middleton, Wisconsin, United Stateslucigen.com ↗

Ownership: Private
Development stage: Other

Overview

Lucigen developed and commercialized a broad portfolio of molecular biology enzymes, reagents, competent cells, cloning systems, and NGS kits. These products support applications in clinical diagnostics development, drug discovery research, synthetic biology, gene editing workflows and more. The company’s assets include ISO 13485-compliant manufacturing capabilities. In 2018 it was acquired by LGC to strengthen their genomics product offering.

Modalities: EnzymeProteinDNA/RNA extraction kits
Industry: Non-Drug Biotech

Partnerships

Custom OEM & partnership opportunities with other life science companies

Beyond the preview

Go deeper on Lucigen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lucigen.